Moderna has dosed the first U.S. participant in the Phase 1 trial of mRNA-4200, an off-the-shelf mRNA cancer antigen therapy being evaluated with checkpoint inhibitors for advanced solid tumors.
Written By: Rishabh Sonawane, BPharm
Reviewed By: Pharmacally Editorial Team
Moderna has announced that the first U.S. participant has been dosed in the Phase 1 clinical trial evaluating mRNA-4200, an investigational off-the-shelf tumour-targeted cancer antigen therapy, in combination with immune checkpoint inhibitors for patients with advanced or metastatic solid tumours.
The milestone marks the clinical entry of Moderna’s third off-the-shelf cancer antigen therapy candidate and further expands the company’s mRNA-based oncology development pipeline. The first participant was enrolled and treated at START Mountain Region in Salt Lake City, Utah, part of The START Centre for Cancer Research, which specialises in early-phase oncology studies.
Phase 1 Clinical Trial Design
The ongoing Phase 1 study (NCT06880549) is an open-label, multicentre, dose-escalation trial designed to evaluate the safety and tolerability of mRNA-4200 administered in combination with checkpoint inhibitor therapy in adults with advanced or metastatic solid tumours. As a first-in-human study, the trial will assess escalating dose levels to characterise the safety profile of mRNA-4200 and support its future clinical development.
Mechanism of Action of mRNA-4200
Unlike personalised cancer vaccines, which are manufactured individually for each patient, mRNA-4200 is being developed as an off-the-shelf mRNA therapeutic intended for broad use across multiple solid tumour types. The investigational therapy encodes seven tumour-associated antigens shared across patients and tumour types. Following administration, the mRNA is designed to produce these antigens in the body, helping induce and expand tumour-specific T-cell responses against selected tumour targets. When administered in combination with immune checkpoint inhibitors, the therapy is designed to stimulate antitumour immune responses by targeting multiple shared tumour antigens simultaneously rather than a single molecular target.
Collaboration Supporting Target Discovery
mRNA-4200 was developed through Moderna’s collaboration with Immatics under the companies’ Database Program. The therapeutic candidate incorporates tumour-associated targets identified using Immatics’ proprietary XPRESIDENT® target discovery and validation platform together with its XCUBE® bioinformatics and artificial intelligence platform. These technologies are designed to identify clinically relevant shared tumour antigens with the potential for broad applicability across multiple cancer indications.
Clinical Perspective
David Berman, M.D., Ph.D., Chief Development Officer at Moderna, said mRNA-4200, the company’s third off-the-shelf cancer antigen therapy candidate, reflects its strategy to develop broadly applicable cancer immunotherapies by targeting multiple shared tumour antigens. Dr. William McKean,
Clinical Investigator at START Mountain Region, said dosing the first participant marks the beginning of evaluating a novel therapeutic approach with the potential to expand treatment options for patients with advanced cancers while generating clinical evidence to support further research.
Development Significance for Moderna’s Oncology Pipeline
Moderna continues to expand its oncology portfolio by leveraging its mRNA platform beyond infectious diseases. The company’s cancer pipeline includes both individualised neoantigen therapies and off-the-shelf cancer antigen therapies designed to generate targeted immune responses against malignant cells across a range of tumour types.
Path Forward
The initiation of the Phase 1 study represents an important milestone in the clinical development of mRNA-4200 as Moderna evaluates a multi-antigen mRNA therapeutic approach for advanced solid tumours. Data from this first-in-human study are expected to characterise the safety and tolerability of mRNA-4200 and support future clinical development of the investigational therapy in combination with immune checkpoint inhibitors.
Reference
About the Writer
Rishabha Sonawane, B.Pharm (LinkedIn) is healthcare writer with a strong interest in medical writing, regulatory affairs, clinical research, and AI-driven drug discovery. He has completed specialized training from the NIH and ICMR in clinical pharmacology, clinical research, and scientific writing. Passionate about evidence-based healthcare communication, he focuses on translating complex scientific research into clear, accurate, and engaging medical content.